Skip to main content
Barbara Iwanik on Muck Rack

Barbara Iwanik

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barbara

Contact Barbara, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

ddMVAC versus gemcitabine–cisplatin as neoadjuvant treatment for muscle-invasive urothelial bladder cancer: a multicenter real-world study

|
By Mateusz Malik, Dawid Sigorski, Zbyszko Chowaniec, Marek Gełej, Krzysztof Tupikowski, Adam Maciejczyk, Barbara Radecka, Tomasz Lewandowski, Lubomir Bodnar, Rodryg Ramlau, Piotr Jacyk, Jacek Ornat, Katarzyna Czerko, Anna Kopczyńska, Barbara Iwanik, Ewelina Kołodziejska, Radosław Piszczek, Zenona Jabłońska
| Nature Verified
Abstract Cisplatin-based neoadjuvant chemotherapy (NACT) followed by radical cystectomy (RC) is the standard treatment for eligible patients with muscle-invasive bladder cancer (MIBC). However, the comparative effectiveness of gemcitabine/cisplatin (GC) and dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in routine practice remains insufficiently defined, particularly in broader real-world populations that include patients with regional lymph node involvement.
Open in Who Shared Issue with article?
See all 1 articles